Contrasting Cardio Diagnostics (NASDAQ:CDIO) & Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oruka Therapeutics and Cardio Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	4	2	3.33
Cardio Diagnostics	0	0	1	0	3.00

Oruka Therapeutics presently has a consensus target price of $41.25, suggesting a potential upside of 80.68%. Cardio Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 812.41%. Given Cardio Diagnostics’ higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Oruka Therapeutics.

Profitability

This table compares Oruka Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Cardio Diagnostics	-22,358.43%	-312.97%	-189.57%

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Oruka Therapeutics and Cardio Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	N/A	N/A
Cardio Diagnostics	$39,138.00	127.06	-$8.38 million	N/A	N/A

Oruka Therapeutics has higher earnings, but lower revenue than Cardio Diagnostics.

Volatility and Risk

Oruka Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 4.87, suggesting that its stock price is 387% more volatile than the S&P 500.

Summary

Oruka Therapeutics beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.